Trials / Completed
CompletedNCT00413036
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 217 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lenalidomide | once daily oral capsule |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2011-04-01
- Completion
- 2011-05-01
- First posted
- 2006-12-19
- Last updated
- 2017-03-01
- Results posted
- 2013-04-11
Locations
53 sites across 7 countries: United States, Canada, France, Germany, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00413036. Inclusion in this directory is not an endorsement.